Key investment points:
The Shanghai and Shenzhen pharmaceutical industry SW index lost 300 this week. From May 16 to May 20, 2022, SW pharmaceutical and biological industry fell by 2.01%, underperforming the CSI 300 index by about 4.24 percentage points in the same period. Among the three-level segments, only blood products and offline pharmacies recorded positive earnings, up 1.60% and 1.33% respectively; Other sectors recorded negative gains, with vaccines falling the most, down 6.35%.
This week, the pharmaceutical and biological industry had a net inflow of 515 million yuan. From May 16 to May 20, 2022, the land stock connect had a net inflow of RMB 15.218 billion, of which the Shanghai Stock connect had a net inflow of RMB 11.489 billion and the Shenzhen Stock connect had a net inflow of RMB 3.729 billion. In the Shenwan industry, the net inflow of banks ranks first and the net outflow of real estate ranks first. This week, the pharmaceutical and biological industry had a net inflow of 515 million yuan, which was slightly higher than that of last week.
Industry news. Recently, the United Kingdom, the United States, Portugal, Spain, Italy, Sweden, Australia and other countries reported confirmed or suspected cases of human monkeypox virus infection. Monkeypox is usually a self limiting disease, and most patients recover within a few weeks. Severe cases are common in children or people with immune deficiency, and are also related to the basic health status of infected people, the degree of exposure to virus and the severity of complications.
Maintain the recommended rating of the industry. Monkeypox cases are found in many countries, and there may be theme investment opportunities for short-term related testing reagent companies. In the medium and long term, we still need to return to fundamentals. It is suggested to pay attention to the high-quality stocks in the segments with good performance and sufficient growth potential or the high-quality leaders whose performance is expected to usher in an inflection point. For example, CXO company: Wuxi Apptec Co.Ltd(603259) ( Wuxi Apptec Co.Ltd(603259) ), Hangzhou Tigermed Consulting Co.Ltd(300347) ( Hangzhou Tigermed Consulting Co.Ltd(300347) ), Pharmaron Beijing Co.Ltd(300759) ( Pharmaron Beijing Co.Ltd(300759) ), Joinn Laboratories (China) Co.Ltd(603127) ( Joinn Laboratories (China) Co.Ltd(603127) ), Asymchem Laboratories (Tianjin) Co.Ltd(002821) ( Asymchem Laboratories (Tianjin) Co.Ltd(002821) ), Porton Pharma Solutions Ltd(300363) ( Porton Pharma Solutions Ltd(300363) ), Kyushu Pharmaceutical ( Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) ), Shanghai Medicilon Inc(688202) ( Shanghai Medicilon Inc(688202) ), etc; Subdivided leaders of scientific services: Shanghai Aladdin Biochemical Technology Co.Ltd(688179) ( Shanghai Aladdin Biochemical Technology Co.Ltd(688179) ), Acrobiosystems Co.Ltd(301080) ( Acrobiosystems Co.Ltd(301080) ), Suzhou Nanomicro Technology Co.Ltd(688690) ( Suzhou Nanomicro Technology Co.Ltd(688690) ), Nanjing Vazyme Biotech Co.Ltd(688105) ( Nanjing Vazyme Biotech Co.Ltd(688105) ), Shanghai Titan Scientific Co.Ltd(688133) ( Shanghai Titan Scientific Co.Ltd(688133) ), etc; Nucleic acid normalization testing is carried out in many places across the country, and diagnostic service companies are expected to benefit: Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) ( Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) ), Dian Diagnostics Group Co.Ltd(300244) ( Dian Diagnostics Group Co.Ltd(300244) ); Medical equipment companies: Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) ( Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) ), Tofflon Science And Technology Group Co.Ltd(300171) ( Tofflon Science And Technology Group Co.Ltd(300171) ), Truking Technology Limited(300358) ( Truking Technology Limited(300358) ), Iray Technology Company Limited(688301) ( Iray Technology Company Limited(688301) ), Qingdao Novelbeam Technology Co.Ltd(688677) ( Qingdao Novelbeam Technology Co.Ltd(688677) ), etc; China’s sporadic epidemic has been gradually controlled, and the demand is expected to rise, leading medical and American leaders Imeik Technology Development Co.Ltd(300896) ( Imeik Technology Development Co.Ltd(300896) ) and Bloomage Biotechnology Corporation Limited(688363) ( Bloomage Biotechnology Corporation Limited(688363) ); Chain medical faucet Aier Eye Hospital Group Co.Ltd(300015) ( Aier Eye Hospital Group Co.Ltd(300015) ); OK mirror faucet Autek China Inc(300595) ( Autek China Inc(300595) ); Eye instrument faucet Eyebright Medical Technology(Beijing) Co.Ltd(688050) ( Eyebright Medical Technology(Beijing) Co.Ltd(688050) ); Brands with friendly policies and lower valuation: China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) ( China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) ), Beijing Tongrentang Co.Ltd(600085) ( Beijing Tongrentang Co.Ltd(600085) ), etc; Retail pharmacies whose performance growth is expected to pick up: Dashenlin Pharmaceutical Group Co.Ltd(603233) ( Dashenlin Pharmaceutical Group Co.Ltd(603233) ), Yifeng Pharmacy Chain Co.Ltd(603939) ( Yifeng Pharmacy Chain Co.Ltd(603939) ), Lbx Pharmacy Chain Joint Stock Company(603883) ( Lbx Pharmacy Chain Joint Stock Company(603883) ), Yixintang Pharmaceutical Group Co.Ltd(002727) ( Yixintang Pharmaceutical Group Co.Ltd(002727) ), etc. Pay attention to Shanghai Junshi Biosciences Co.Ltd(688180) ( Shanghai Junshi Biosciences Co.Ltd(688180) ) and others with smooth progress in the research and development of covid-19 specific drugs.
Risk tip: covid-19 epidemic continues to repeat, industry competition intensifies, product price reduction, product safety and quality risk, policy risk, R & D progress is lower than expected, etc.
